DE1692463A1 - Stimulant for the growth and development of animals and poultry and processes for the production thereof - Google Patents
Stimulant for the growth and development of animals and poultry and processes for the production thereofInfo
- Publication number
- DE1692463A1 DE1692463A1 DE19671692463 DE1692463A DE1692463A1 DE 1692463 A1 DE1692463 A1 DE 1692463A1 DE 19671692463 DE19671692463 DE 19671692463 DE 1692463 A DE1692463 A DE 1692463A DE 1692463 A1 DE1692463 A1 DE 1692463A1
- Authority
- DE
- Germany
- Prior art keywords
- amount
- derivatives
- salts
- cysteine
- stimulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001465754 Metazoa Species 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 244000144977 poultry Species 0.000 title claims description 6
- 238000000034 method Methods 0.000 title claims description 5
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 18
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims description 9
- 239000004312 hexamethylene tetramine Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 6
- 235000010234 sodium benzoate Nutrition 0.000 claims description 6
- 239000004299 sodium benzoate Substances 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 4
- 229960001763 zinc sulfate Drugs 0.000 claims description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 150000001945 cysteines Chemical class 0.000 claims description 3
- JWWCMTHTYFLEPN-UHFFFAOYSA-M lithium;2-sulfooxybenzoate Chemical compound [Li+].OS(=O)(=O)OC1=CC=CC=C1C([O-])=O JWWCMTHTYFLEPN-UHFFFAOYSA-M 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- 239000000021 stimulant Substances 0.000 claims description 3
- 239000000834 fixative Substances 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 1
- 229960003885 sodium benzoate Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 description 8
- 229960004011 methenamine Drugs 0.000 description 7
- 230000037396 body weight Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- IFQSXNOEEPCSLW-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride Chemical compound Cl.SCC(N)C(O)=O IFQSXNOEEPCSLW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- YYRMJZQKEFZXMX-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca+2].OP(O)(O)=O.OP(O)(O)=O YYRMJZQKEFZXMX-UHFFFAOYSA-N 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002426 superphosphate Substances 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- LGFVFTLVGHGRRL-UHFFFAOYSA-L calcium;2-sulfooxybenzoate Chemical compound [Ca+2].OS(=O)(=O)OC1=CC=CC=C1C([O-])=O.OS(=O)(=O)OC1=CC=CC=C1C([O-])=O LGFVFTLVGHGRRL-UHFFFAOYSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- -1 ilatriu Chemical compound 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 208000012639 Balance disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000010181 polygamy Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229950000329 thiouracil Drugs 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
*». Iswpatotf I D U / 4 D* ». Iswpatotf I D U / 4 D
—tt Or. E Sinn·, I MMm, Uopohfctr. 39/lV —T t Or. E Sinn ·, I MMm, Uopohfctr. 39 / IV
Ministerul Industrie! Chirnice, BukarestMinisterul Industry! Chirnice, Bucharest
"Stimulans Tür das Wachstum und die Entwicklung von Tieren, von Geflügel sowie Verfahren zur Herstellung"Stimulant door the growth and development of animals, poultry and methods of manufacture
desselben."same. "
Die vorliegende Erfindung betrifft ein Stimulans, welches an Tiere verabreicht wird, um deren Körpergewicht zu erhöhen, das Verhältnis Fleisch/Fett zu steigern, die Produktion von Milch anzuregen, die Sterilität Infolge von Hormonstörungen bei Tieren zu bekämpfen, die Wolle von Schafen elastischer und widerstandsfähiger zu machen und eine Erhöhung dee Körpergewichts von Geflügel zu bewirken.The present invention relates to a stimulant which is administered to animals in order to increase their body weight, to increase the meat / fat ratio, to stimulate the production of milk, to combat sterility as a result of hormonal disorders in animals, the wool of sheep to make them more elastic and resilient and to increase the body weight of poultry.
Die Erfindung betrifft ferner ein Verfahren zur Herstellung des Stimulans-Produktes.The invention also relates to a method for producing the stimulant product.
BADBATH
209808/0440209808/0440
Zahlreiche Verfahren für die Stimulierung des Wachstums von Tieren und die Produktion von Milch sind bereits bekannt. Die einen Verfahren zielen darauf ab, den Appetit der Tiere zu erhöhen, während die anderen die Schilddrüsenaktivität inhibieren, um die Stoffwechselverfahren oder dergl. herabzusetzen. Die zu diesem Zweck auf oralem oder parenteralem Wege verabreichten Substanzen sind sehr zahlreich und unterscheiden sich sowohl hinsichtlich ihrer chemischen Struktur als auch ihres biochemischen Mechanismus. Die einen Substanzen sind Derivate von Thioharnstoff, Thiouracil oder Thiazol, während die anderen aus verschiedenen organischen Säuren, Mineralsäuren oder deren Salzen bestehen. Es wurden auch bereits Hormone und Vitamine, die gegebenenfalls mit Spurenelementen wie Phosphor, Zink» Calcium, ilatriu», Kupfer oder dergl. vermischt sind, verabreicht. Die Verwendung von Cystein oder Homoeystein zur Steigerung der Milchproduktion bei Tieren ist ebenfalls bekannt·Numerous methods for stimulating the growth of animals and producing milk are already known. the one method aims to increase the animals' appetite while the other inhibits thyroid activity, to lower metabolic processes or the like. Those administered for this purpose by the oral or parenteral route Substances are very numerous and differ in both their chemical structure and theirs biochemical mechanism. One substances are derivatives of thiourea, thiouracil or thiazole, while the other consist of various organic acids, mineral acids or their salts. There were also hormones and Vitamins that may be mixed with trace elements such as phosphorus, zinc, calcium, ilatriu, copper or the like, administered. The use of cysteine or homoeysteine for Increasing milk production in animals is also known
Die bekannten Stlnülantlen besitzen verschiedene Nachteile, von denen einige allerdings keine große Rolle spielen· Diese Nachteile sind auf ihre Natur sowie ihre Wirkung zurückzuführen, die sie auf Stoffwechselverfahren ausüben· Beispielsweise seien eine Steigerung der Proteinsyntheee, eile auf bestimmte Substanzen zurückzuführen 1st, oder eine Störung des HormongleiohgewichteB, welche mit Fettansatz und einer Ansanolung von Wasser verbunden 1st und auf bestimmte andere 3ubetanzen zurückzuführen ist, erwähnt· Die auf der Basis von Cystein oder Homocyatein erzeugtenThe known Stlnülantlen have various disadvantages, some of which, however, do not play a major role · These Disadvantages are due to their nature as well as the effect they exert on metabolic processes · For example an increase in protein synthesis, rush to certain substances or a hormonal balance disorder which is associated with the formation of fat and the solution of water and can be traced back to certain other substances mentioned. Those made on the basis of cysteine or homocyateine
209808/0A40209808 / 0A40
Produkte besitzen den Nachteil, daß sie nicht aufbewahrt werden können, da sie in wäßriger Lösung instabil sind. Dies hat den Nachteil zur Folge, daß derartige Produkte schnell ihre Wirksamkeit verlieren.Products have the disadvantage that they cannot be stored because they are unstable in aqueous solution. This has the The disadvantage is that such products quickly lose their effectiveness.
Die vorliegende Erfindung beseitigt die den bisher bekannten Stimulantien anhaftenden Nachteile insofern, al.J urfindungsgernüJo ::in stabile;; ;Jtimulansprodui:t zur Verfügung jcatell" wiru, das eine wesentliche Rolle bei tier Steigerung -er Proucinsynthese in dem Organismus spielt. Das erfindungsgeraäße Stimulans besteht aus Derivaten oder Salzen von Cystein oder aessen Homologen, wie beispielsweise Homocystein, den cyclischen Derivaten des Cyateins oder des Homocysteins sowie deren Salzen, wobei diese Verbindungen in dem Organismus auf enzymatischem Wece sehr reaktionsfähige Thiolgruppen in Freiheit setzen, die eine wichtige Rolle bei der Synthese von Nukleinsäuren und bei der Proteinsynthese, hinsichtlich der Stimulierung der enzymatischen Aktivität, der Erhöhung der Konzentration an Vitamin-Coenzymen, der Stimulierung der Hormonaktivität sowie insbesondere der Aktivität von endrogenen und östrogenen Hormonen spielen.The present invention eliminates the disadvantages inherent in the previously known stimulants insofar as al.J urfindungsgernüJo :: in stable ;; ; Jtimulansprodui: t available jcatell " Wiru that plays an essential role in increasing the synthesis of prucin plays in the organism. The stimulant according to the invention consists of derivatives or salts of cysteine or aessen homologues, such as homocysteine, the cyclic derivatives of cyatein or homocysteine and their salts, where these compounds in the organism by enzymatic means Set free very reactive thiol groups, which play an important role in the synthesis of nucleic acids and in the Protein synthesis, in terms of stimulating enzymatic activity, increasing the concentration of vitamin coenzymes, the stimulation of hormonal activity and in particular the activity of endrogenic and estrogenic hormones.
Das erfindungS£GKiäße Stimulans wird hergescello, indem in Wasser f> ;o Cysteinchlorhydrat, seine Salze oder Derivate oder diejenigen .seiner Homologen in Oejenwarir eines Aldehyds oder eines potentiellen Aläehyas, wio beispielsweise Hexamethylenjtetramin, in einer lienge von C,5 /' aufgelöst werden, worauf dieThe inventive stimulant is hergescello by adding in Water f>; o cysteine chlorohydrate, its salts or derivatives or those. of its homologues in Oejenwarir of an aldehyde or of a potential alaehya, such as hexamethylene tetramine, can be resolved in a length of C, 5 / ', whereupon the
209808/0440 ^- r^^^A209808/0440 ^ - r ^^^ A
Zugabe von Folsäure in einer Menge von 0,1 %, Natriumbenzoat in einer Menge von 1,2 #, anschließend von Calcium- und Lithiumsulfosalicylat in einer .Menge von 0,5 #, Natriummetabisulfit in einer Menge von 1,5 %» Superphosphat in einer Menge von 2,6 % und Zinksulfat in einer Menge von 0,10 % erfolgt. Die Zumischung von Lithium- und Calolumsulfosallcylat sowie von Folsäure dient dazu, den Hauptwirkstoff zu aktivieren, da Lithium- und Calclurnsulfosalicylat die Diffusion des Stimulans in das Gewebe zu steigern vermögen. Der Phosphor spielt eine wichtige Rolle bei Stoffwechselverfahren, während dem Zink eine Rolle hinsichtlich der Aktivität bestimmter Enzyme zukommt. Zink stimuliert die Aktivität der Sexualhormone und gonadotropen Hormone. In dieser Zusammensetzung kommt dem Hexamethylentetramin die Rolle des potentiellen Aldehyds zu· Der Srsatz der Cystelnderivate oder dessen Homologen durch cyclische Derivate macht die Anwesenheit eines Aldehyds oder potentiellen Aldehyds, wie beispielsweise Hexamethylentetramin* Überflüssig* Das Natriumbenzoat erhöht die Löslichkeit der Folsäure in der Lösung und stabilisiert diese, während das Natrlummetablsulfit die Aktivität des Hauptwirkstoffs stimuliert.Addition of folic acid in an amount of 0.1 %, sodium benzoate in an amount of 1.2 #, then calcium and lithium sulfosalicylate in an amount of 0.5 #, sodium metabisulfite in an amount of 1.5 % » superphosphate in an amount of 2.6 % and zinc sulfate in an amount of 0.10 % . The addition of lithium and calcium sulfosalicylate as well as folic acid serves to activate the main active ingredient, since lithium and calcium sulfosalicylate are able to increase the diffusion of the stimulant into the tissue. Phosphorus plays an important role in metabolic processes, while zinc plays a role in the activity of certain enzymes. Zinc stimulates the activity of sex hormones and gonadotropic hormones. In this composition, the hexamethylenetetramine takes on the role of the potential aldehyde.The substitution of the cysteline derivatives or its homologues with cyclic derivatives makes the presence of an aldehyde or potential aldehyde, such as hexamethylenetetramine * superfluous * The sodium benzoate increases the solubility of the folic acid in the solution and stabilizes it this, while the sodium tablet sulfite stimulates the activity of the main active ingredient.
Die folgenden Beispiele erläutern die Erfindung, ohne sie zu beschränken.The following examples illustrate the invention without restricting it.
2Q9808/O44O2Q9808 / O44O
Zur Herstellung von 100 g des Stimulansproduktes in Form eines Pulvers werden folgende Substanzen verwendet:For the production of 100 g of the stimulant product in the form of a Powder, the following substances are used:
Cysteinchlorhydrat 5 gCysteine chlorohydrate 5 g
Hexamethylentetramin 0,5 SHexamethylenetetramine 0.5 S
Polsäure 0,1 gPoly acid 0.1 g
Natriumbenzoat 1,2 gSodium benzoate 1.2 g
Calcium- und Lithiumsulfosalicylat 1,2 gCalcium and lithium sulfosalicylate 1.2 g
Natriuranetabisulfit 1,5 gNatriuranetabisulfite 1.5 g
Superphosphat 2,6 gSuperphosphate 2.6 g
Zinksulfat 0,10 gZinc sulfate 0.10 g
destilliertes Wasser bis 100 gdistilled water up to 100 g
Die erhaltene Lösung wird bis zur Trockne eingedampft. Der Ersatz der Derivat· von Cystein oder dessen Homologen durch ihre cyclischen Derivate macht die Anwesenheit eines Aldehyds oder potentiellen Aldehyds, wie beispielsweise Hexamethylentetramin,The resulting solution is evaporated to dryness. The replacement of the derivative of cysteine or its homologues by their cyclic derivatives makes the presence of an aldehyde or potential aldehyde, such as hexamethylenetetramine,
Überflüssig, wobei auch in diesem Falle die Herstellung der Lösung und ihre Verdampfung bis zur Trockne nicht mehr erforderlich 1st, da die vorstehend erwähnten Komponenten in Form eines Pulvers homogenisiert werden können, welches gut verschlossen aufbewahrt werden muß. Das unter diesen Bedingungen erhaltene Produkt wird täglich oder alle 2 bis J Tage, gelöst in einer bestimmten Menge Wasser, die ralt der zu verfütternden Futtermenge, Vielehe befeuchtet wird, schwankt, morgens verabreicht oder in eine solche Menge Wasser· eingebracht, die geringerSuperfluous, although in this case too the production of the Solution and its evaporation to dryness no longer required 1st, because the above-mentioned components can be homogenized in the form of a powder which is well sealed must be kept. The product obtained under these conditions is dissolved daily or every 2 to J days in a certain amount of water corresponding to the amount of water to be fed Amount of food, polygamy is moistened, fluctuates, administered in the morning or introduced into such an amount of water that is less
209808/0440209808/0440
ist als die Wassermenge, welche morgens von den Tieren getrunken wird, damit die Aufnahme der vollständigen Menge des verabreichten Stimulans gewährleistet ist.is the amount of water that the animals drink in the morning so that they can absorb the full amount of the administered Stimulant is guaranteed.
Die Verabreichung auf oralem Wege ermöglicht ferner die Verwendung einer Mischung des Stimulans in Form eines Pulvers zusammen mit Futterprodukten, ohne daß dabei eine vorherige Auflösung in Wasser erforderlich ist. Die Dosis des auf diese Weise an Tiereund Geflügel verabreichten Stimulans beträgt 1 g pro 50 bis 500 kg Körpergewicht.Administration by the oral route also enables use a mixture of the stimulant in the form of a powder together with food products without prior dissolution in water is required. The dose of stimulant thus administered to animals and poultry is 1 g per 50 up to 500 kg body weight.
Zur Herstellung einer injizierbaren Lösung werden folgendeTo prepare an injectable solution, the following are used
Substanzen verwendet:Substances used:
Cys teinchlorhydrat Hexamethylentetramin FolsäureCysteine chlorohydrate hexamethylenetetramine Folic acid
Natriumbenzoat Calcium- und Lithiumsulfosalicylat Natriumaietabisulfit Superphosphat ZinksulfatSodium benzoate, calcium and lithium sulfosalicylate Sodium aietabisulfite Superphosphate zinc sulfate
üestilliertes Wasser bis zu einem Volumendistilled water to volume
209808/0440209808/0440
Di· erhaltene Lusting wird auf einen pH-tfert von 5 bis 6 eingestellt und anschließend tyndallisiert oder sterilisiert. Durch Ersatz der Gystelnderivate oder, deren Homologen durch ihre cyclischen Derivate wird die Anwesenheit eines Aldehyds oder potentiellen Aldehyds, wie beispielsweise Hexamethylentetramin, Überflussig.The lusting obtained is adjusted to a pH of 5 to 6 and then tyndallized or sterilized. By Replacement of the Gysteln derivatives or their homologues by their cyclic derivatives, the presence of an aldehyde or potential aldehyde, such as hexamethylenetetramine, Superfluous.
Das Produkt wird subkutan oder intramuskulär Jeden Tag verabreicht, wobei jedoch während der ersten Waehstumsperiode der Tiere die Verabreichung duroh Einspritzen nur*alle 3 bis 4 Tage erfolgt· Die verabreichte Dosis beträgt 1 g pro 100 bis 500 kg Körpergewicht. Di« Verwendung von Hilf sstibs tanzen in dem Stiaulansprodukt ern&gliaht eine Irhuhußg der Stimulaneaktivität des Hauptwirkstoffs, volmi ditse Aktivität größer ist als dl· «titulierend« tflrkung* if«leh# bei dem getrennten Einsatz der einzelnen Subatanzen erslelt wird.The product is administered subcutaneously or intramuscularly every day, but during the first period of growth Animals administration by injection only * every 3 to 4 The dose administered is 1 g per 100 to days 500 kg body weight. The use of auxiliary sstibs dance in The Stiaulansproduct increases the stimulus activity of the main active ingredient and increases its activity is as dl · «titling« tflrkung * if «leh # in the case of the separated Use of the individual subatanzen is erslelt.
208883/0440208883/0440
Claims (2)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO5194966 | 1966-07-27 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE1692463A1 true DE1692463A1 (en) | 1972-02-17 |
| DE1692463B2 DE1692463B2 (en) | 1973-02-22 |
| DE1692463C3 DE1692463C3 (en) | 1973-10-04 |
Family
ID=20086539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1692463A Expired DE1692463C3 (en) | 1966-07-27 | 1967-06-29 | Livestock and poultry growth and development promoting agent containing cysteine and homocysteine |
Country Status (7)
| Country | Link |
|---|---|
| AT (1) | AT283811B (en) |
| BE (1) | BE700249A (en) |
| DE (1) | DE1692463C3 (en) |
| FR (1) | FR1570434A (en) |
| GB (1) | GB1180252A (en) |
| IT (1) | IT1061786B (en) |
| NL (1) | NL6709066A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2469131A1 (en) * | 1979-11-14 | 1981-05-22 | Riker Laboratories Inc | Animal feed contg. thiazolidine 4:carboxylic acid - to increase rate of growth and milk yield |
| DE4017964A1 (en) * | 1990-06-05 | 1991-12-12 | Baensch Tetra Werke | MEDICAL FEED FOR THE SYSTEMATIC TREATMENT OF EECTOPARASITIES AND EKTOBACTERIAL DISEASES OF ORNAMENTAL AND COMMERCIAL FISH |
| US10206415B2 (en) * | 2016-08-02 | 2019-02-19 | Zinpro Corporation | Folic acid rumen by-pass method and composition |
| US10219528B2 (en) | 2016-08-02 | 2019-03-05 | Zinpro Corporation | Folic acid, metal complexes for rumen by-pass nutritional supplementation of ruminants |
-
1967
- 1967-06-13 GB GB27190/67A patent/GB1180252A/en not_active Expired
- 1967-06-15 IT IT17261/67A patent/IT1061786B/en active
- 1967-06-21 BE BE700249D patent/BE700249A/xx unknown
- 1967-06-27 AT AT598667A patent/AT283811B/en not_active IP Right Cessation
- 1967-06-29 DE DE1692463A patent/DE1692463C3/en not_active Expired
- 1967-06-29 NL NL6709066A patent/NL6709066A/xx unknown
- 1967-07-20 FR FR1570434D patent/FR1570434A/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IT1061786B (en) | 1983-04-30 |
| DE1692463B2 (en) | 1973-02-22 |
| FR1570434A (en) | 1969-06-13 |
| NL6709066A (en) | 1968-01-29 |
| GB1180252A (en) | 1970-02-04 |
| BE700249A (en) | 1967-12-01 |
| DE1692463C3 (en) | 1973-10-04 |
| AT283811B (en) | 1970-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69429990T2 (en) | Use of isovaleramide as a mild anxiolytic and sedative | |
| DE2323187A1 (en) | PROCESS FOR THE PRODUCTION OF A STABILIZED POWDERED SECRETIN PREPARATION BY FREEZE-DRYING | |
| DE69322958T2 (en) | STABILIZED SOMATOTROPINE FOR PARENTERAL ADMINISTRATION | |
| DE1915798A1 (en) | Anti-acidic drugs | |
| DE1692463A1 (en) | Stimulant for the growth and development of animals and poultry and processes for the production thereof | |
| DE69628754T2 (en) | EASILY ABSORBABLE CALCIUM COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF | |
| CH624098A5 (en) | ||
| DE2709506A1 (en) | MEDICINAL PRODUCTS CONTAINING 10-DEAZAMINOPTERIN | |
| EP0236855A1 (en) | Pharmaceutical composition | |
| DE69936056T2 (en) | FOOD SUPPLEMENT CONTAINING LIPONIC ACID AND CREATINE AND METHODS FOR THEIR APPLICATION | |
| DE3505572A1 (en) | INJECTABLE SOLUTION, PARTICULARLY FOR TREATING KETOSIS, AND METHOD FOR PRODUCING THE SAME | |
| DE2731013C2 (en) | Process for the preparation of an aqueous solution for infusion | |
| CH634546A5 (en) | METHOD FOR PRODUCING COMPLEX COMPOUNDS OF AMINODICARBONIC ACIDS WITH MAGNESIUM AND HALOGENS. | |
| DE60122701T2 (en) | COSMETIC OR DERMATOLOGICAL CREAM PREPARATION, THEIR PREPARATION AND USE | |
| DE2635293A1 (en) | SALT MIXTURE, IN PARTICULAR EASILY ASSIMILABLE MEDICINAL MIXTURE WITH INCREASED SOLUBILITY, CONTAINS CALCIUM SALTS AND / OR MAGNESIUM SALTS | |
| DE2848182C3 (en) | Complementary feed for cattle and process for its preparation | |
| DE2036113A1 (en) | Tetramisole preparations | |
| EP0799237B1 (en) | Vitamin b 12-containing sallow thorn concentrates or extracts | |
| DE1670234A1 (en) | New liver protection preparation as well as its application and production | |
| DE1767447C (en) | Orally administrable, storable pharmaceutical preparation containing 5,6-benzimidazole-cobamide coenzyme as active ingredient | |
| DE3229955A1 (en) | Pharmaceutical compositions with analgesic action | |
| DE2454164A1 (en) | Injections against magnesium tetany in ruminants - contg. a basic magnesium salt of acetylglutamic acid | |
| EP0341527A2 (en) | Agent for increasing animal growth | |
| DE3026772A1 (en) | INJECTABLE SULFONAMIDE / POTENTIATOR PREPARATION AND METHOD FOR THE PRODUCTION THEREOF | |
| DE2022653C (en) | Growth-promoting combination of active ingredients for livestock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| E77 | Valid patent as to the heymanns-index 1977 | ||
| EHJ | Ceased/non-payment of the annual fee |